Third, GLP-1 analogue like liraglutide, DPP-4 inhibitor like exenatide and sitagliptin, SGLT two inhibitor like empagliflozin, and PPARγ agonist like rosiglitazone are new anti-diabetes agents under development. Here, PPARG is linked to diabetes mellitus.